The earnings call presented a strong financial performance with significant revenue growth and positive clinical trial results, despite challenges such as pricing declines and CVS exclusion impacting the growth rate.

Company Guidance

In the Lilly Q2 2025 earnings call, the company reported a robust revenue growth of 38% compared to Q2 2024, driven by key products such as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio, and Zepbound. Specifically, Mounjaro, which recently became the market leader in the U.S. for type 2 diabetes incretin prescriptions, contributed significantly to this growth, with new launches in countries like Mexico and Brazil. The company also noted a strong financial performance in the first half of 2025, raising its revenue and earnings per share guidance. The effective tax rate remained consistent at 16.5%, while earnings per share rose 61% to $6.31. Lilly's gross margin as a percentage of revenue increased to 85%, with R&D expenses rising by 23% due to higher late-stage asset expenses. The company also highlighted its strategic investments in manufacturing capacity, achieving a production increase of more than 1.6 times the salable incretin doses produced in the first half of 2025 compared to the same period in 2024.

Robust Revenue Growth

Revenue grew 38% compared to Q2 2024, driven by key products such as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio, and Zepbound.

Positive Clinical Trial Results

Positive top line data from the ATTAIN-1 orforglipron trial showed patients lost more than 27 pounds or 12.4% of their body weight. Orforglipron also improved key markers of metabolic health.

FDA and European Approvals

U.S. FDA approval of a new dosing schedule for Kisunla and positive European CHMP opinion for Kisunla.

Growth in Incretin Analog Class

Lilly gained market share in the incretin analog class for the fourth quarter in a row, with Mounjaro becoming the market leader in the U.S. for type 2 diabetes incretin prescriptions.

Increased Production Capacity

Produced more than 1.6x the amount of salable incretin doses in the first half of 2025 compared to the first half of 2024.

Financial Milestones

Raised revenue and earnings per share guidance for 2025. Earnings per share increased 61% to $6.31.

Eli Lilly & Co (LLY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LLY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	6.36 / -	1.18	―	―	―
Aug 07, 2025	2025 (Q2)	5.60 / 6.31	3.92	60.97% (+2.39)
May 01, 2025	2025 (Q1)	3.26 / 3.34	2.58	29.46% (+0.76)
Feb 06, 2025	2024 (Q4)	5.04 / 5.32	2.49	113.65% (+2.83)
Oct 30, 2024	2024 (Q3)	1.42 / 1.18	0.1	1080.00% (+1.08)
Aug 08, 2024	2024 (Q2)	2.74 / 3.92	2.11	85.78% (+1.81)
Apr 30, 2024	2024 (Q1)	2.47 / 2.58	1.62	59.26% (+0.96)
Feb 06, 2024	2023 (Q4)	2.30 / 2.49	2.09	19.14% (+0.40)
Nov 02, 2023	2023 (Q3)	-0.18 / 0.10	1.98	-94.95% (-1.88)
Aug 08, 2023	2023 (Q2)	1.98 / 2.11	1.25	68.80% (+0.86)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LLY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$744.73	$639.46	-14.14%
May 01, 2025	$895.14	$790.74	-11.66%
Feb 06, 2025	$837.17	$865.19	+3.35%
Oct 30, 2024	$896.72	$840.40	-6.28%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.